TAVR Gets Love, MitraClip Gets None In Medicare Inpatient Proposal
This article was originally published in The Gray Sheet
CMS proposes to grant new hospital inpatient payment categories for transcatheter valve replacements, a potential boon to Edwards’ and Medtronic’s devices. But the Medicare agency continues to stand firm against upgrading payment levels for Abbott’s MitraClip percutaneous mitral valve repair procedure.
You may also be interested in...
CMS agreed to grant new tech add-on payments to St. Jude’s CardioMEMS implantable heart failure monitoring system and Abbott’s MitraClip mitral valve repair system, but it took some convincing. The agency also granted an add-on for NeuroPace’s RNS responsive neurostimulator system to treat seizures.
Edwards Lifesciences reported 19 percent year-over-year growth in worldwide sales of its Sapien transcatheter aortic valve systems during the second quarter of 2014. The company cites the ongoing launch of the Sapien 3 system in Europe and Sapien XT in the U.S. as keys to continuing growth.
A new draft national Medicare coverage policy offers to pay for transcatheter mitral valve repair procedures with devices like Abbott’s MitraClip only if they are conducted by a qualified heart team and are part of a national registry.